in this study. Eligible patients must have received a script for a reimbursed DMT for RRMS between September 2011 and February 2016. Patients were classified into five age-groups (ages 18–30; 31–40; 41–50; 51–60; 61+) and defined as persistent if their DMT script was filled within 4 months. Persistence was derived using the Kaplan-Meier method and hazard ratios (HR) to represent the relative rate of drop-off of different age groups.

Results Patients aged 18–30 (n=250) had a 44% increased risk of discontinuation (HR 1.44 (95%CI: 1.22–1.72) compared to the ‘all ages’ cohort (n=1,866); no significant difference was observed for any other age group (HRs between 1.08 and 0.92). Patients in this 18–30 age-group had a significantly higher risk of discontinuation on injectable therapy (glatiramer acetate, interferon beta-1a, interferon beta-1b) compared to those on non-injectable therapy (dimethyl fumarate, fingolimod, natalizumab, teriflunomide) (HR 2.42 (95% CI: 1.63–3.61)).

Conclusions Patients aged 18–30 were the least persistent age group in this study. Patients aged 18–30 were less persistent on injectable than non-injectable DMTs.

051 OVERLAPPING SYNDROME OF GIANT CELL ARTERITIS AND ANCA-ASSOCIATED VASCULITIS COMPLICATED BY SEVERE AXONAL NEUROPATHY: A CASE REPORT

Laura Perju-Dumbrava1, Fariha Islam2, Rohitha Makonahalli3, Catriona McLean2, Hedley Griffiths4, Alzheek Mahaota1, Neurology, Barwon Health, Geelong, VIC, Australia; 2Anatomical Pathology, Alfred Hospital, Melbourne, VIC, Australia; 3Rheumatology, Barwon Health, Geelong, VIC, Australia

Case A 61-year-old woman presented with what was thought to be a refractory, temporal artery biopsy-proven giant cell arteritis (GCA). After 4 months of therapy she was unable to get the prednisolone dose below 40 mg/day, so weekly subcutaneous Tocilizumab was introduced but with minimal response after 8 weeks. She was then admitted to hospital with a severe rapidly progressive length dependent sensorimotor peripheral neuropathy. Nerve conduction studies showed predominantly an axonal neuropathy with multiple pseudoconduction blocks.

Sural nerve and gastrocnemius biopsies revealed a necrotising vasculitis with numerous giant cells and active axonal degeneration. She proved to be ANCA-PR3 positive, without other systemic manifestations. ANCA-associated vasculitic neuropathy was diagnosed and she was treated with two 1 g Rituximab infusions, 2 weeks apart.

On follow-up after a month, she had regained some strength but still required a wheelchair for mobility. Further Rituximab infusion after 6 months is planned; prednisolone has been successfully weaned to 10 mg/day.

Conclusion Peripheral nerve involvement, which is relatively common in ANCA-associated vasculitis, has also been reported in 14% of GCA cases. But ANCA-PR3 positivity is rare in biopsy-proven GGA, with only a handful of well-documented cases.

Heightened suspicion of an alternative diagnosis in the face of an unusual clinical course (lack of steroid response and appearance of small vessel vasculitic symptoms for what is accepted to be a large vessel vasculitis) is critical and our experience highlights the important fact that a diagnosis of one of these disorders does not preclude the subsequent diagnosis of the other.

References

054 IMPACT OF ONLINE ADULT HEADACHE GUIDELINE ON HEADACHE REFERRAL TO NEUROLOGY CLINIC

Leon Huang, David Bourke*, Anna Ranta. Capital and Coast District Health Board, Wellington, Wellington, New Zealand

Introduction Headache is a common problem in primary care and is one of the main reasons for general practitioners to...

Abstracts

053 GLUT-1 DEFICIENCY PRESENTING AS DOPA-RESPONSIVE DYSTONIA: AN ATYPICAL PHENOTYPE OF A RARE DISEASE

Sophie E Waller1, Jeffrey Blackie, Himanshu Goel. Department of Neurology, John Hunter Hospital, New Lambton Heights, NSW, Australia; 2John Hunter Hospital, New Lambton Heights, NSW, Australia

Introduction The SLC2A1 gene encodes the glucose transporter GLUT1, responsible for normal glucose transport across the blood-brain barrier. Mutations in this gene have classically been associated with an epileptic encephalopathy referred to as GLUT-1 Deficiency Syndrome, which typically presents with early-onset refractory epilepsy, developmental delay and complex movement disorders.1,2 More recently, SLC2A1 variants have been identified in patients with paroxysmal exercise-induced dyskinesia (PED), with or without a history of epilepsy.3,4 Response to medication is typically poor; however, both seizures and dyskinesia may improve following implementation of a ketogenic diet.5 A single case of levodopa responsiveness has previously been described in a subject with SLC2A1 mutation and PED.5

Methods and results We describe a 47-year-old female with mild intellectual disability since childhood but no history of epilepsy, who developed episodic dystonia affecting the lower limbs in her early 20’s. A clinical diagnosis of dopa-responsive dystonia was made following a marked, sustained response to levodopa. There was no significant family history. In her 40’s she developed breakthrough dystonia with exertion and choreiform movements affecting the fingers and face. A subsequent dystonia panel identified a heterozygous variant c.[1199G>T]; [ urinary arg400leu] in the SLC2A1 gene. Cerebrospinal fluid glucose concentration was low (2.0 mmol/L). She declined a trial of a ketogenic diet.

SLC2A1 variants are associated with PED; however, response to levodopa has not been widely reported.

Conclusion It is becoming increasingly evident that the phenotypic presentations of GLUT1 deficiency are diverse, and SLC2A1 testing should be considered in a broader range of patients.

References